Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Abuse Potential of PF614
NCT05567354Phase 1Completed
- Sponsor
- Ensysce Biosciences
- Start
- Jun 2022
- Primary completion
- Aug 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF614 (3 arms), sponsored by Ensysce Biosciences. Primary endpoints: Peak Maximum Effect (Emax) for Drug Liking (At this Moment) Visual Analog Scale and Take Drug again Visual Analog Scale (Emax). Started Jun 2022; status: completed.
02
Drugs
PF614
Beyond the preview
Go deeper on NCT05567354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05567354.